期刊文献+

特比萘芬联合派瑞松霜治疗念珠菌性包皮龟头炎的疗效观察 被引量:5

Observition of Therapeutic Effect of Terbinafine and Pevisone Cream in the Treatment of Candidal Balanoposthitis
下载PDF
导出
摘要 目的探讨特比萘芬(Terbinafine)联合派瑞松霜(PevisoneCream)治疗念珠菌性包皮龟头炎的临床疗效及安全性。方法选择确诊患者95例,随机分为两组,治疗组50例,采用特比萘芬250mg顿服,每天1次,连服2周,同时给予派瑞松霜外涂,每天早晚各1次,连用2周;对照组45例,单纯给予派瑞松霜外涂,用法及疗程同治疗组;停药2周后复诊观察疗效及真菌清除率。结果治疗组痊愈30例,占60%,对照组治愈17例,占38%;两组治愈率比较,差异有显著性(χ2=4.679,P<0.05);治疗组有效45例,占90%,对照组有效33例,占73%;两组有效率比较,差异有显著性(χ2=4.478,P<0.05);两组均无明显不良反应。结论特比萘芬联合派瑞松霜治疗念球菌性包皮头炎的效果确切、痊愈率高,且副反应少。 Objective To investigate the clinical efficacy and safety of Terbinafine and Pevisone Cream in the Treatment of Candidal Balanoposthitis.Methods ninety-five patients were randomly divided into two groups. Fifty were treated with Terbinafine 250,po,qd on base of Pevisone Cream for two weeks. Forty-five were only treated with Pevisone Cream treatments for two weeks. The clinical efficacy and safety was analyzed.Results In theTerbinafine and Pevisone Cream group in the treatment of Candidal Balanoposthitis, the total cure rates were 60 %, the total effective rates were 90%, the total mycological cure rates were 92 %; In the control group, the total cure rates were 38 %, the total effective rates were 73% , the total mycologicl cure rates were 87 %. The adverse reaction were no found. Using ?2 test, significant differences were found between the two groups(P<0.05).Conclusion Terbinafine and Pevisone Cream treatment were effective and safe in treating onychomycosis and significantly decreased the courses of candidal balanoposthitis, suggesting that it is a preferable therapy for candidal balanoposthitis.
出处 《中国实用医药》 2006年第5期35-36,共2页 China Practical Medicine
关键词 特比萘芬 派瑞松霜 念珠菌性包皮龟头炎 Terbinafine Pevisone Cream candidal balanoposthitis treatment
  • 相关文献

参考文献6

二级参考文献25

  • 1Espinel-Ingroff A. Related Articles. Clinical relevance of antifungal resistance[J]. Infect Dis Clin North Am, 1997, 11(4): 929-944.
  • 2Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing:. conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole,itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards[J]. Clin Infect Dis, 1997, 24(2): 235-247.
  • 3Lynch ME, Sobel JD, Fidel PL. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis[J]. J Med Vet Mycol, 1996, 34(5): 337-339.
  • 4Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis[J]. Clin Infect Dis, 1992, 14( Suppl 1): S148-153.
  • 5National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts:approved standard. NCCLS document M-27A[S]. Wayne, Pennsylvania,NCCLS, 1997.
  • 6Ryder NS, Wagner S, Leitner I. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother,1998, 42: 1057-1061.
  • 7Segal R, Kritzman A, Cividalli L, et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol, 1996, 35:958-961.
  • 8郭宁如,现代真菌病诊断治疗学,1997年,51页
  • 9王文莉,王端礼,李若瑜,王晓红,万哲.酵母菌的 NCCLS 药敏试验方法及其应用[J].中华医学检验杂志,1997,20(2):119-122. 被引量:37
  • 10李晋波,刘维达.特比萘芬对白念珠菌酵母相和菌丝相抗菌活性的比较[J].中华皮肤科杂志,2000,33(1):53-54. 被引量:21

共引文献175

同被引文献21

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部